Copyright
©The Author(s) 2022.
World J Clin Cases. Feb 16, 2022; 10(5): 1485-1497
Published online Feb 16, 2022. doi: 10.12998/wjcc.v10.i5.1485
Published online Feb 16, 2022. doi: 10.12998/wjcc.v10.i5.1485
Table 1 Baseline characteristics of patients diagnosed with gastric cancer (n = 35, 492) by prior cancer status
Characteristics | No previous cancer, n = 31491 (88.73%) | With prior cancer, n = 4001 (11.27%) | P value | ||
Age (yr) | < 0.001 | ||||
< 65 | 13160 | (41.79%) | 714 | (17.85%) | |
≥ 65 | 18331 | (58.21%) | 3287 | (82.15%) | |
Sex | < 0.001 | ||||
Male | 19479 | (61.86%) | 2777 | (69.41%) | |
Female | 12012 | (38.14%) | 1224 | (30.59%) | |
Race | < 0.001 | ||||
White | 22087 | (70.14%) | 2926 | (73.13%) | |
Black | 4090 | (12.99%) | 555 | (13.87%) | |
AI/AN | 285 | (0.91%) | 16 | (0.4%) | |
AP | 4898 | (15.55%) | 504 | (12.6%) | |
Unknown | 131 | (0.42%) | 0 | (0%) | |
Marital status | < 0.001 | ||||
Married | 17571 | (55.80%) | 2366 | (59.14%) | |
Unmarried | 12473 | (39.61%) | 1416 | (35.39%) | |
Unknown | 1447 | (4.59%) | 219 | (5.47%) | |
Site | |||||
Cardia and Fundus | 10537 | (33.46%) | 1486 | (37.14%) | |
Body of stomach | 6340 | (20.13%) | 844 | (21.09%) | |
Antrum and Pylorus | 7370 | (23.40%) | 862 | (21.54%) | |
Stomach, NOS | 7244 | (23.00%) | 809 | (20.22%) | |
Lymph nodes examined | < 0.001 | ||||
No examined | 16884 | (53.62%) | 2287 | (57.16%) | |
1-15 | 7020 | (22.29%) | 909 | (22.72%) | |
≥ 16 | 6338 | (20.13%) | 686 | (17.15%) | |
Unknown | 1249 | (3.97%) | 119 | (2.97%) | |
Positive lymph nodes | < 0.001 | ||||
0 | 4914 | (36.79%) | 693 | (43.45%) | |
1-2 | 2599 | (19.46%) | 327 | (20.50%) | |
3-6 | 2399 | (17.96%) | 276 | (17.30%) | |
7-15 | 2355 | (17.63%) | 207 | (12.98%) | |
≥ 16 | 1066 | (7.98%) | 89 | (5.58%) | |
Unknown | 25 | (0.19%) | 3 | (0.19%) | |
SEER stage | < 0.001 | ||||
Localized | 7209 | (22.89%) | 1190 | (29.74%) | |
Regional | 8978 | (28.51%) | 1051 | (26.27%) | |
Distant | 12615 | (40.06%) | 1242 | (31.04%) | |
Unstaged | 2689 | (8.54%) | 518 | (12.95%) | |
Grade | < 0.001 | ||||
G1 | 1087 | (3.45%) | 181 | (4.52%) | |
G2 | 7012 | (22.27%) | 1027 | (25.67%) | |
G3 | 18112 | (57.51%) | 2108 | (52.69%) | |
G4 | 567 | (1.80%) | 68 | (1.70%) | |
Unknown | 4713 | (14.97%) | 617 | (15.42%) | |
Surgery | 0.088 | ||||
No | 16692 | (53.01%) | 2194 | (54.84%) | |
Yes | 14630 | (46.46%) | 1785 | (44.61%) | |
Unknown | 169 | (0.54%) | 22 | (0.55%) | |
Radiation | < 0.001 | ||||
None | 23413 | (74.35 %) | 3098 | (77.43%) | |
Radiation | 7789 | (24.73%) | 866 | (21.64%) | |
Unknown | 289 | (0.92%) | 37 | (0.92%) | |
Chemotherapy | < 0.001 | ||||
No/Known | 17189 | (54.58%) | 2569 | (64.21%) | |
Chemotherapy | 14302 | (45.42%) | 1432 | (35.79%) |
Table 2 Overall 3-year survival rate of gastric patients stratified by age
Prior initial cancer site | All-cause survival (95%CI) | ||
Overall | Age < 65 yr (%) | Age ≥ 65 yr (%) | |
No prior cancer | 26.42 (25.90, 26.94) | 28.95 (28.14, 29.77) | 24.49 (23.82, 25.16) |
With prior cancer | 25.20 (23.80, 26.63) | 30.12 (26.68, 33.62) | 24.08 (22.55, 25.65) |
Prostate | 24.79 (21.39, 28.32) | 23.33 (16.23, 31.21) | 25.16 (21.35, 29.14) |
Gastrointestinal | 26.47 (23.96, 29.04) | 31.13 (22.60, 40.03) | 26.00 (23.38, 28.68) |
Hematologic | 28.06 (22.75, 33.58) | 42.17 (31.11, 52.80) | 22.16 (16.49, 28.38) |
Breast | 26.80 (22.96, 30.78) | 33.27 (25.47, 41.25) | 24.36 (20.04, 28.92) |
Genitourinary | 23.64 (20.14, 27.30) | 34.29 (25.39, 43.35) | 21.06 (17.36, 25.02) |
Lung | 19.32 (13.87, 25.45) | 12.50 (3.95, 26.23) | 20.83 (14.64, 27.79) |
Other | 22.90 (18.79, 27.26) | 24.61 (16.44, 33.66) | 22.33 (17.66, 27.35) |
Table 3 Multivariable Cox regression analysis of survival in patients with gastric cancer1
Characteristics | All-cause adjusted HR | P value | Cancer-specific adjusted HR | P value |
Age (yr; vs < 65) | ||||
≥ 65 | 1.32 (1.28, 1.35) | < 0.001 | 1.25 (1.22, 1.29) | < 0.001 |
Sex (vs male) | ||||
Female | 0.93 (0.91, 0.96) | < 0.001 | 0.95 (0.92, 0.98) | < 0.001 |
Race (vs white) | ||||
Black | 1.09 (1.05, 1.13) | < 0.001 | 1.07 (1.03, 1.12) | < 0.001 |
AI/AN | 1.14 (1.01, 1.29) | 0.033 | 1.16 (1.02, 1.32) | 0.023 |
AP | 0.79 (0.76, 0.82) | < 0.001 | 0.79 (0.76, 0.82) | < 0.001 |
Marital status (vs married) | ||||
Unmarried | 1.14 (1.12, 1.17) | < 0.001 | 1.11 (1.08, 1.14) | < 0.001 |
Gastric cancer site (vs cardia and fundus) | ||||
Body of stomach | 0.96 (0.92, 0.99) | 0.013 | 0.93 (0.90, 0.97) | < 0.001 |
Antrum and Pylorus | 0.99 (0.96, 1.03) | 0.727 | 0.97 (0.93, 1.01) | 0.114 |
Lymph nodes examined (vs no examined) | ||||
1-15 | 0.73 (0.69, 0.77) | < 0.001 | 0.72 (0.68, 0.77) | < 0.001 |
≥ 16 | 0.65 (0.61, 0.68) | < 0.001 | 0.66 (0.62, 0.71) | < 0.001 |
Prior history of cancer (vs none) | ||||
Yes | 1.01 (0.97, 1.05) | 0.644 | 0.82 (0.78, 0.85) | < 0.001 |
SEER stage (vs localized) | ||||
Regional | 2.34 (2.26, 2.44) | < 0.001 | 2.83 (2.70, 2.96) | < 0.001 |
Distant | 3.43 (3.31, 3.57) | < 0.001 | 4.35 (4.16, 4.54) | < 0.001 |
Grade (vs G1) | ||||
G2 | 1.19 (1.10, 1.28) | < 0.001 | 1.27 (1.16, 1.38) | < 0.001 |
G3 | 1.56 (1.45, 1.67) | < 0.001 | 1.75 (1.61, 1.91) | < 0.001 |
G4 | 1.60 (1.43, 1.79) | < 0.001 | 1.85 (1.63, 2.09) | < 0.001 |
Surgery (vs none) | ||||
Yes | 0.45 (0.43, 0.48) | < 0.001 | 0.44 (0.42, 0.47) | < 0.001 |
Radiation (vs none) | ||||
Radiation | 0.92 (0.89, 0.95) | 0.007 | 0.92 (0.89, 0.96) | < 0.001 |
Chemotherapy (vs none) | ||||
Chemotherapy | 0.52 (0.51, 0.54) | < 0.001 | 0.53 (0.51, 0.55) | < 0.001 |
Table 4 Multivariable Cox regression analysis of survival in gastric cancer patients stratified by age, stage, and timing of prior cancer (prior cancer vs < none)
Characteristics | All-cause survival (CI) | P value | Gastric cancer-specific survival (CI) | P value |
Age (yr) | ||||
< 65 | 1.08 (1.00, 1.18) | 0.064 | 0.77 (0.69, 0.85) | < 0.001 |
≥ 65 | 1.00 (0.96, 1.04) | 0.843 | 0.83 (0.79, 0.87) | < 0.001 |
Stage | ||||
Localized | 1.10 (1.02, 1.19) | 0.012 | 0.82 (0.74, 0.91) | < 0.001 |
Regional | 0.99 (0.92, 1.06) | 0.777 | 0.84 (0.78, 0.92) | < 0.001 |
Distant | 0.92 (0.87, 0.98) | 0.014 | 0.79 (0.73, 0.85) | < 0.001 |
Timing of prior cancer | ||||
< 5 | 1.03 (0.98, 1.09) | 0.275 | 0.77 (0.72, 0.82) | < 0.001 |
5-10 | 0.98 (0.92, 1.04) | 0.525 | 0.84 (0.78, 0.90) | < 0.001 |
≥ 10 | 1.01 (0.94, 1.08) | 0.811 | 0.88 (0.81, 0.95) | 0.001 |
- Citation: Yin X, He XK, Wu LY, Yan SX. Effect of prior malignancy on the prognosis of gastric cancer and somatic mutation. World J Clin Cases 2022; 10(5): 1485-1497
- URL: https://www.wjgnet.com/2307-8960/full/v10/i5/1485.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i5.1485